Cullinan Therapeutics (NASDAQ:CGEM) reported encouraging initial clinical data and outlined expanded development pathways for its portfolio of dual-targeting T-cell engagers, marking an expansion for the oncology-focused biotech into the autoimmune space.
Artelo Biosciences (NASDAQ:ARTL) announced encouraging human metabolite identification and profiling data for its lead drug candidate, ART26.12, as the biotechnology company aims to de-risk the development of its novel non-opioid pain therapy.
Organon (NYSE:OGN) announced that the US Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Tofidence, expanding the therapeutic indications of the drug within the competitive US biosimilars market.
Core & Main (NYSE:CNM) reported improved financial results for the first quarter of fiscal year 2026, supported by reliable infrastructure demand and active cost navigation in an otherwise mixed industrial environment.
Nvni Group (NASDAQ:NVNI) announced substantial progress toward completing its acquisition of a 51% controlling interest in the holding company operating Beyondsoft Corporation’s consulting and services business across the United States, Brazil, and Singapore.
Tecnoglass (NYSE:TLGS) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.15 per share for the second quarter of 2026.
Harrow (NASDAQ:HROW) announced the formal commercial re-launch of Verkazia, a targeted prescription therapy for vernal keratoconjunctivitis (VKC), an underdiagnosed but severe chronic allergic eye disease that primarily affects children.
Chewy (NYSE:CHWY) delivered a strong financial performance for the first quarter of fiscal year 2026, characterized by robust top-line growth and a significant increase in profitability despite a dynamic broader consumer environment.
APA Corporation (NASDAQ:APA) announced an agreement to acquire Savant Alaska for approximately $70 million in upfront cash, moving to lock down strategic midstream and field infrastructure on Alaska's eastern North Slope.
Opera (NASDAQ:OPRA) announced that its Board of Directors has declared a semi-annual cash dividend of $0.40 per share for holders of its ordinary shares and American Depositary Shares (ADSs).
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
